Teva Buys Emalex for $900M Tourette Drug
April 29, 2026
Teva to acquire Emalex Biosciences for $700M upfront + $200M milestones to add NDA-ready ecopipam for paediatric Tourette syndrome.
April 29, 2026
Teva to acquire Emalex Biosciences for $700M upfront + $200M milestones to add NDA-ready ecopipam for paediatric Tourette syndrome.